National Polytechnic Institute, Mexico   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Mexico City Mexico (1936)

Organization Overview

First Clinical Trial
2000
NCT02346188
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional-UI | Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional | Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV) | National Polytechnic Institute, Mexico

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Cognitive Dysfunction (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Febrile Neutropenia (Phase 2)

Fever (Phase 2)

Infections (Phase 2)

Neutropenia (Phase 2)

Pulmonary Valve Insufficiency (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Respiratory Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 23